Indeed, studies using 18F-FLT in EGFR mutation positive NSCLC have shown that a decrease of 18F-FLT uptake in tumor lesions is associated with response to EGFR TKI treatment (10, 36, 37). This evidence concerns the gene EGFR and non-small cell lung carcinoma.